HC Wainwright Reaffirms “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 2.11% from the […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 2.11% from the […]
